Clinical trial NCT03414021: Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor
Official title: Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thyroid Diseases
Heart Diseases
Bone Diseases
Brain Diseases
Kidney Diseases
Keywords: Nuclear Medicine
SPECT-CT Scan
gamma-camera with semiconductor
Lead sponsor: Lille Catholic University
Sponsor class: OTHER
First posted: 2018-01-29
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Every patient referred to our departments of nuclear medicine for a nuclear médicine exploration

Brief summary: Since 2017, a revolution began in the departments of nuclear medicine, with the routine use of gamma-cameras with semiconductor. These gamma-cameras (which obtained the CE-marking in 2016), offer a technological breakthrough by providing an additional information. They allow "to quantify" for the 1st time in clinical routine conditions, the quantity of radioactivity, by means of a "SUVspect", in a volume of interest, while respecting the recommendations of best practice of the learned societies of French nuclear medicine (SFMN), European (EANM) and American (SNM), without injection of tracer nor acquisition or additional irradiation. The SUVspect is therefore an indicator of the quantity of tracer in a given volume of acquisition.

Until now, the interpretation criteria of scintigraphies are based on the homogeneity of distribution of a tracer in the explored organ (for single organs such as the heart or the thyroid, for example) or in the asymmetry of distribution of the tracer (for the double organs, such as the kidney or the joints).

This new gamma-camera allows to study the distribution of the radio-tracers in "list" mode, allowing to retrospectively reconstruct the images in various ways (for example, by modifying the size of the matrix of acquisition, the energy windows, the time of acquisition). Therefore, we can simulate and propose modifications in current procedures.

Every patient referred to our department of nuclear medicine to undergo a scintigraphy with a tracer of nuclear medicine (with a marketing authorization) can, while benefiting from an examination by this gamma-camera, to be the object of this study, and to profit from this additional information.

So, without changing the diagnosis or the usual care, we wish to take advantage of this additional information to improve the criteria of interpretation of our examinations.

This possibility being new, there is no available bibliography (our department is the 5th department of nuclear medicine in Europe to equip itself with this large field-of-view gamma-camera CZT, the DNM 670, made by General Electric), while 2961 articles speak about the SUVmax (in PET) in Pubmed.


Eligibility criteria: Inclusion Criteria:

- informed adult patients referred to our department of nuclear medicine for a nuclear medicine exploration

Exclusion Criteria:

* Refusal to participate
* Patient under guardianship

Primary outcomes:
measure: SUVspect
timeFrame: 5 years
Secondary outcomes:
measure: Matrix size
timeFrame: 5 years
measure: duration of image acquisition
timeFrame: 5 years
Other outcomes:
Locations:
city: Lomme
country: France
facility: Humanitep
state: Hauts De France
city: Lille
country: France
facility: Hopital Privé Le Bois
state: Hauts-de-France
Study officials:
affiliation: GIE HUMANITEP, GHICL
name: Tanguy Blaire, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: GIE HUMANITEP, GHICL
name: Alban Baillez, MD
role: PRINCIPAL_INVESTIGATOR
References: